- Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes. Itoga A, Zha X, Nagase K, Aoki Y, Ito H, Yokoyama O.
BMJ Open Diabetes Res Care. 2020 May;8(1):e001111. doi: 10.1136/bmjdrc-2019-001111.
- Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial. Takahashi S, Kato K, Takei M, Yokoyama O, Gotoh M.
Int J Urol. 2021 Jan;28(1):82-90. doi: 10.1111/iju.14411. Epub 2020 Nov 3
- Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients. Kobayashi H, Tsuchiyama K, Taga M, Tokunaga T, Ito H, Yokoyama O. Medicine (Baltimore). 2021 Apr 9;100(14):e25397. doi: 10.1097/MD.0000000000025397.
- Urinary reabsorption in the rat kidney by anticholinergics. Oe H, Yoshiki H, Zha X, Kobayashi H, Aoki Y, Ito H, Yokoyama O. Sci Rep. 2021 Apr 28;11(1):9191. doi: 10.1038/s41598-021-88738-y.
- Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension. Honda M, Yokoyama O, Takahashi R, Matsuda T, Nakayama T, Mogi T.
Int J Urol. 2021 Sep;28(9):906-912. doi: 10.1111/iju.14602. Epub 2021 Jun 1.
- Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study. Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K.
Neurourol Urodyn. 2021 Aug;40(6):1651-1660. doi: 10.1002/nau.24732. Epub 2021 Jun 17
- Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. Yokoyama O, Honda M, Yamanishi T, Sekiguchi Y, Fujii K, Kinoshita K, Nakayama T, Ueno A, Mogi T. Int Urol Nephrol. 2021 Nov;53(11):2243-2250. doi: 10.1007/s11255-021-02962-z. Epub 2021 Jul 22.
- Duration of smoking cessation is negatively associated with the magnitude of chronic prostatic inflammation and storage dysfunction in patients with benign prostatic hyperplasia:
Inamura S, Ito H, Oe H, Seki M, Taga M, Kobayashi M, Yokoyama O. Int J Urol. 2020 Oct;27(10):874-881. doi: 10.1111/iju.14320. Epub 2020 Jul 24.
- Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats: Hisato Kobayashi, Xinmin Zha, Keiko Nagase, So Inamura, Minekatsu Taga, Yoshitaka Aoki, Hideaki Ito, Osamu Yokoyama: Life Sci. 2022 Mar 31;298:120504. doi: 10.1016/j.lfs.2022.120504. Online ahead of print.
- Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M, Takeda M, Gotoh M, Yokoyama O, Kakizaki H, Takahashi S, Masumori N, Nagai S, Minemura K.
BJU Int. 2020 Jan 28. doi: 10.1111/bju.15020. [Epub ahead of print]
PMID: 31991511